Immunoglobulin therapy in Guillain-Barré syndrome in children.
Autor(es): Nicolaides P.; Appleton R. E.
Resumo: Four children with evolving Guillain-Barré syndrome were treated with a five-day course of intravenous immunoglobulin. No patient showed further progression of the condition and all made a rapid and complete recovery with no evidence of relapse over a six- to 24-month follow-up period. The early use of immunoglobulin in this disorder may prevent further progression of the disease and accelerate short-term recovery, with resulting medical, social and financial implications.
Imprenta: Developmental Medicine and Child Neurology, v. 37, n. 12, p. 1110-1114, 1995
Identificador do objeto digital: 10.1111/j.1469-8749.1995.tb11972.x
Descritores: Guillain-Barre Syndrome - Proteins ; Guillain-Barre Syndrome - Public health
Data de publicação: 1995
